Nerve cells, also known as neurons are the fundamental units of the brain and nervous system, responsible for receiving and transmitting information throughout the body. Rich with multiple neuronal cell types and varied glial cells, neural tissue has historically been difficult to model in vitro [1]. Such modelling challenges greatly slow our progress in understanding and treating neurodegenerative disease. Fortunately, this is changing with recent advances in induced pluripotent stem cell (iPSC) technology.
91̽’s deterministic cell programming technology (known as DZپ-dz™) enables the rapid conversion of entire cultures of stem cells into a precise cell identity with unprecedented consistency. The rapid gain of functionality of 91̽’s human nerve cells empower researchers to build the types of physiologically relevant in vitro models needed to drive research into neurodegenerative disease and neuropsychiatric disorders, and the data-backed lot-to-lot consistency enables standardisation across assays used in early stages of drug discovery, from target identification to clinical translation.
Dive into this application note, to discover how ioGlutamatergic Neurons and iPSC-derived astrocytes have been used in 3D microtissues, to build a powerful model system for medium- to high-throughput drug screening and more productive preclinical drug development.
91̽
Dr Deepak Srivastava | King’s College London
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 91̽
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | 91̽
Emmanouil Metzakopian | Vice President, Research and Development | 91̽
Javier Conde-Vancells | Director Product Management | 91̽
Tom Brown | Senior Product Manager | 91̽
Marcos Herrera Vaquero, PhD | Senior Scientist | 91̽Ben Bar-Sadeh, PhD | Senior Scientist | Anima Biotech
Tom Brown | Senior Product Manager | 91̽
The 91̽ ioCells portfolio includes human iPSC-derived GABAergic, Glutamatergic, Motor, and Sensory Neurons. Powered by opti-ox technology, these cryopreserved, post-mitotic cells offer unmatched lot-to-lot consistency at scale, enabling standardisation across research and drug discovery workflows.
Unlike primary neurons that often lack suitable controls, 91̽’s ioCells portfolio includes ioDisease Model Cells engineered with disease-relevant mutations for conditions such as ALS, Alzheimer’s, and Parkinson’s disease, these can be paired with genetically matched ioWild Type Cells to enable true experimental comparisons. Access to defined human neurons enables scientists to study neurodegenerative disease in a human physiologically relevant context.
The ioCells portfolio of human iPSC-derived glutamatergic, GABAergic, sensory and motor neurons rapidly gain functionality and are ideal for building physiologically relevant in vitro models. They can be co-cultured with glial cells and other neuronal subtypes to simulate the complex networks needed to drive research into neurodegenerative and neurological disorders.
1. Pereira I, Lopez-Martinez MJ, Samitier J. (2023) Advances in current in vitro models on neurodegenerative diseases. doi: .